Patent · US Expired

Cellular retinoic acid binding protein II as a marker for breast cancer

US7579158B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Gabriele Pestlin · Birkenfeld, DE
Herbert Andres · Penzberg, DE
Peter Berndt · Basel, CH
Marie-Luise Hagmann · Penzberg, DE
Johann Karl · Peißenberg, DE
Hanno Langen · Steinen, DE
Werner Zolg · Weilheim in Oberbayern, DE

Key dates

Filing date	Dec 5, 2005
Grant date	Aug 25, 2009
Priority date	—
Expiry date	Dec 5, 2025

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70567
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.